



25 May 2023

ASX ANNOUNCEMENT

IMPEDIMED ANNOUNCES FIRST PUBLISHED MEDICAL POLICY COVERING BIOIMPEDANCE SPECTROSCOPY TESTING FOR BREAST CANCER PATIENTS

ImpediMed Limited (ASX:IPD) is pleased to announce the first published medical policy covering bioimpedance spectroscopy (BIS) testing using ImpediMed's SOZO® Digital Health Platform (SOZO) for lymphoedema in breast cancer patients and survivors.

Key Points

- **Priority Health¹ in Michigan published the first medical policy covering BIS testing using SOZO for lymphoedema in breast cancer patients and survivors.**
- The policy specifically names SOZO and defines the use of SOZO and BIS as medically necessary in the detection, diagnosis or surveillance of secondary, subclinical breast cancer related lymphoedema.
- The medical policy was amended specifically for BIS.
- The recently announced update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Survivorship was a critical factor to support this published medical policy.
- The reimbursement rate under the published policy is expected to be more than 50% higher than the current national average for Medicare reimbursement for SOZO and testing frequency is based on medical necessity, supporting the Private Payor payment and testing protocol assumptions used in customer return on investment (ROI) models for SOZO.

Reimbursement Strategy

- Regional Payors are a key first step in gaining broad coverage and this published medical policy starts a domino effect.
- With this medical policy publication, the Company expects reaching critical mass (>80% covered lives) in a key target state this quarter².
- The Company also projects nearly 50% of Private Payors to publish coverage by the end of the calendar year 2023 and nearly all Private Payors to publish coverage by the end of the fiscal year 2024.
- Once broad coverage for BIS testing for lymphoedema is achieved for breast cancer, the Company will be well positioned to begin expanding into other cancers.

A link to the medical policy may be found here:

<https://www.priorityhealth.com/provider/manual/news/standards/05-24-2023-may-2023-medical-policy-updates>

Commenting on the published medical policy, ImpediMed Managing Director and Chief Executive Officer, Richard Valencia said, "This first published medical policy is a key accomplishment in our reimbursement

¹ Priority Health is a top two Regional Payor in Michigan and is a nationally recognised nonprofit health benefits company focused on improving the health and lives of 1,000,000 members across Michigan.

² Projected timing based on a combination of direct correspondence from private payors to ImpediMed or to our provider partners, as well as publicly available BIS medical policy publishing updates.

For personal use only



strategy to achieve broad coverage of lymphoedema testing using ImpediMed's SOZO® Digital Health Platform, which is the only FDA-cleared and commercially available BIS technology for lymphoedema assessment. We expected the first published medical policy to be from a Regional Payor, and we continue to expect that this publication will start a domino effect, motivating other Private Payors, both in the same state and neighboring states, to publish positive medical policies supporting the use of BIS.”

Approved for release by the Managing Director & CEO, Richard Valencia.

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

For personal use only



Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only